



DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA S.A.
 SA Registration Number 13165/06/B/86/14
 4, KIFISSIAS AVENUE & ERYTHROU STAVROU STR, GR-15123 MAROUSI, ATHENS
 Data and information for the period from January 1st 2010 to December 31st 2010

(published pursuant to codified law.2190, article 135, for enterprises compiling annual financial statements, consolidated or not, in accordance with the IFRS)

The data and information below resulting from the financial statements aim at an overall presentation of the Group and parent company DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS-HYGEIA S.A financial situation and results. We, therefore, propose to readers, prior to any investment choice or transaction with the issuer, to visit the issuer's web address where the financial statements and the audit report by the chartered accountant, whenever required, are posted.

COMPANY GENERAL INFORMATION		CASH FLOW STATEMENT (CONSOLIDATED OR NOT CONSOLIDATED)			
Competent Service Prefecture: Ministry of Development and Commerce, Public Companies and Credit Web address: www.hygeia.gr Board of Directors composition: Chairman: Konstantinos Stavrou Deputy Chairman: Vgenopoulos Andreas BoD members: Souvatzoglou Areti-CEO, Komninos Alexios, Efstratiadis Georgios Non executive members: Gogoulakis Sotirios, Kyprianidis Anastasios, Maroudis Christos, Seitanidis Vassileios, Zacharopoulos Georgios Dedoulis Evangelos Independent non executive members: Moustakas Meletios, Edipidis Alexandros Approval date by the Board of Directors of the Annual Financial Statements: March 28, 2011 Certified auditor: Manolis Michailios (Institute of Certified Public Accountants of Greece (SOEL) registration Audit Firm: Grant Thornton SA (Institute of Certified Public Accountants of Greece (SOEL) registration Type of Audit Report: By consent		Amounts in €			
		Group		Company	
		01/01-31/12/2010	01/01-31/12/2009	01/01-31/12/2010	01/01-31/12/2009
OPERATING ACTIVITIES					
Profit/(Loss) before tax (Continuing operations)		(81.521.968)	20.487.505	(62.199.431)	18.296.337
Profit/(Loss) before tax (Discontinued operations)		(4.578.830)	(3.114.791)	0	0
Plus / minus adjustments for:					
Depreciations		20.266.510	20.263.319	8.042.368	7.947.587
Assets impairment		44.316.750	0	62.910.000	0
Provisions		9.457.423	4.367.143	1.640.935	1.972.637
Income from use of provisions of previous financial years		(881.502)	(572)	0	0
Unrealized gains from fx translation differences		684.313	484.740	0	279.770
Results (income, expenses, profits and losses) from investment activities		1.725.624	(3.289.696)	1.780.460	(11.441.149)
Amortization of grants		(213.574)	(143.053)	(46.966)	(19.661)
Profit/Loss from associates		0	20.568	0	0
Interests on debt and similar charges		11.312.987	14.194.743	6.807.168	9.839.960
Employees' stock option plan		283.568	572.293	283.568	572.293
Plus/minus adjustments for changes in working capital accounts or changes related to operating activities:					
Decrease/ (increase) in inventories		530.530	(1.017.627)	(698.036)	303.302
Decrease / (increase) in receivables		(7.397.598)	(23.472.018)	(18.048.991)	(4.829.249)
(Increase / decrease in other current assets accounts		(9.106.371)	10.427.417	0	3.323.261
(Decrease) / increase in liabilities (minus loans)		26.026.052	(16.959.061)	12.065.984	(5.606.195)
Operational Cash flows from discontinued operations		6.143.337	3.520.419	0	0
Less:					
Interests on debt and similar paid up charges		(8.402.552)	(15.131.828)	(4.406.998)	(12.173.803)
Tax paid		(9.261.458)	(8.687.131)	(2.316.118)	(354.365)
Total inflow / (outflow) from operating activities (a)		(616.759)	2.522.370	5.813.943	8.110.725
Investment activities					
Acquisition of subsidiaries, associates, joint ventures and other investments		(210.703)	(23.875.669)	0	(20.962.749)
Purchase of tangible and intangible fixed assets		(38.402.436)	(37.678.997)	(10.016.720)	(9.735.403)
Proceeds from tangible and intangible fixed assets sales		261.440	210.319	0	60.000
Grants received		257.998	264.538	0	98.304
Purchase of available for sale portfolio		0	(51.418)	0	0
Loans to associates		0	0	(14.764.072)	(14.671.710)
Sales of trading portfolio		0	(31.959)	0	0
Interests received		294.350	2.488.378	205.304	2.073.950
Dividends received		9.130	0	24.880	10.801.235
Investment Cash flows from discontinued operations		(700.634)	(446.369)	0	0
Total inflow / (outflow) from investment activities (b)		(38.490.855)	(59.121.177)	(24.550.608)	(32.336.373)
Financing activities					
Share capital increase receivables		11.193.022	82.703.708	11.040.022	82.703.708
Payments for share capital decrease in non controlling interest of subsidiaries		0	(6.787.069)	0	(6.281.546)
Inflows/(outflows) from differences of shareholdings in subsidiaries		(450.000)	323.849.222	0	275.000.000
Proceeds from loans		99.230.903	(493.268.434)	67.400.000	(479.953.140)
Repayment of loans		(37.312.533)	0	(29.900.000)	0
Settlement of liabilities from financing leases (amortizations)		(941.001)	0	0	0
Capital return		(24.498.027)	(15.411.512)	(24.498.027)	(15.075.709)
Dividends paid		(117.677)	(1.834.540)	0	0
Financing Cash flows from discontinued operations		(807.015)	127.597	0	0
Total inflow / (outflow) from financing activities (c)		46.297.672	(110.621.028)	24.041.995	(143.606.687)
Net increase / (decrease) in cash and cash equivalents of the period (a) + (b) + (c)		7.190.058	(167.219.835)	5.305.330	(167.832.335)
Cash and cash equivalents at the beginning of period		28.999.036	199.550.702	21.695.860	189.807.965
Cash and cash equivalents at the beginning of period from discontinued operations		112.261	0	0	0
Cash and cash equivalents at the end of period from discontinued operations		133.258	112.261	0	0
Fx translation differences in cash and cash equivalents from continuing operations		(214.294)	(3.244.975)	0	(279.770)
Fx translation differences in cash and cash equivalents from discontinued operations		0	25.405	0	0
Cash and cash equivalents at the end of period		35.917.942	29.111.297	27.001.190	21.695.860

STATEMENT OF CHANGES IN EQUITY (CONSOLIDATED OR NOT CONSOLIDATED)				
Amounts in €				
	Group		Company	
	31/12/2010	31/12/2009	31/12/2010	31/12/2009
Total equity at the beginning of the period (01.01.2010 and 01.01.2009, respectively)	431.366.712	383.338.652	397.613.947	324.316.483
Total comprehensive income after tax (continued and discontinued operations)	(91.614.064)	955.358	(64.416.765)	13.557.638
Direct changes in Equity	0	0	0	(1.017.380)
Share capital increase	11.129.474	82.703.708	11.129.474	82.703.708
Employees' stock option plan	283.568	572.293	283.568	572.293
Purchase of subsidiaries	(20.244)	(30.921)	0	0
Dividends to non controlling interest of subsidiaries	(117.677)	(761.910)	0	0
Increase/(Decrease) of non controlling interest rate in subsidiaries	(450.000)	(10.880.667)	0	0
Dividends to non controlling interest	0	(1.974.428)	0	0
Decrease of non controlling interest rate from the sale of shareholdings in subsidiaries	69.575	0	0	0
Convertible bond loan reserve	0	(1.161.544)	0	(1.161.540)
Distribution of Dividends	0	(6.281.546)	0	(6.281.546)
Capital return	(24.498.027)	(15.112.283)	(24.498.027)	(15.075.709)
Total equity at the end of the period (31.12.2010 and 31.12.2009, respectively)	326.149.317	431.366.712	320.112.197	397.613.947

INCOME STATEMENT (CONSOLIDATED OR NOT CONSOLIDATED)			
Amounts in €			
	Company		
	01/01-31/12/2010	01/01-31/12/2009	
Revenues	139.742.237	141.423.841	
Gross profit	18.088.024	25.980.482	
Profits before taxes, financing and investing results			
Profit/(Loss) before tax	7.779.698	16.965.534	
Profit/(Loss) after tax (A)	(62.199.431)	18.296.337	
- Parent company owners	(64.416.765)	13.557.638	
- Minority interest	(64.416.765)	13.557.638	
Other total income after tax (B)	0	0	
Total comprehensive income after tax (A) + (B)	(64.416.765)	13.557.638	
- Parent company owners	(64.416.765)	13.557.638	
- Minority interest	0	0	
Earnings/ (losses) per share after tax-basic (in €)	(0,3846)	0,1230	
Profit before taxes, financing and investing results and depreciations (EBITDA)	18.035.506	24.922.505	

	Group		
	Continuing operations	Discontinued operations	Total
Revenues	299.012.827	15.643.742	314.656.569
Gross profit/(losses)	16.402.903	(1.300.224)	15.102.679
Profits/(losses) before taxes, financing and investing results	(24.712.575)	(3.748.509)	(28.461.084)
Profit/(Loss) before tax	(81.521.968)	(5.034.060)	(86.556.028)
Profit/(Loss) after tax (A)	(87.106.744)	(4.110.351)	(91.217.095)
- Parent company owners	(77.561.324)	(1.986.984)	(79.548.308)
- Minority interest	(9.545.420)	(2.123.367)	(11.668.787)
Other total income after tax (B)	(396.969)	0	(396.969)
Total comprehensive income after tax (A) + (B)	(87.503.713)	(4.110.351)	(91.614.064)
- Parent company owners	(77.891.590)	(1.986.984)	(79.878.574)
- Minority interest	(9.612.118)	(2.123.367)	(11.735.485)
Earnings/ (losses) per share after tax-basic (in €)	(0,4631)	(0,0119)	(0,4750)
Profit/(losses) before taxes, financing and investing results and depreciations (EBITDA)	(2.511.800)	(2.659.368)	(5.171.168)

	Group		
	Continuing operations	Discontinued operations	Total
Revenues	336.704.462	16.679.198	353.383.660
Gross profit	54.888.348	46.658	54.935.006
Profits/(losses) before taxes, financing and investing results			
Profit/(Loss) before tax	31.658.092	(2.346.656)	29.311.436
Profit/(Loss) after tax (A)	20.487.505	(3.114.791)	17.372.714
- Parent company owners	7.256.522	(3.358.190)	3.898.332
- Minority interest	10.696.239	(1.758.835)	8.937.404
Other total income after tax (B)	(3.439.717)	(1.599.556)	(5.039.273)
Total comprehensive income after tax (A) + (B)	(2.942.974)	0	(2.942.974)
- Parent company owners	4.313.548	(3.358.190)	955.358
- Minority interest	3.329.027	(1.758.835)	1.570.192
Earnings/ (losses) per share after tax-basic (in €)	984.522	(1.599.356)	(614.834)
Profit/(losses) before taxes, financing and investing results and depreciations (EBITDA)	0,0971	(0,0160)	0,0811
Profit/(losses) before taxes, financing and investing results and depreciations (EBITDA)	50.790.230	(1.367.037)	49.423.193

ADDITIONAL DATA AND INFORMATION

- The Group companies with their respective shareholding rates and their integration method in the consolidated financial statements of the period 01.01 - 31.12.2010 are included in Note 5 & 9 of the Annual Financial Statement Notes.
- These notes also include (a) the subsidiary "BIO-CHECK INTERNATIONAL Private Multi-medical Facility Iatriki S.A", not included in the respective comparable period of 2009, when it was included for seven months, (b) Primary Medicine SA, included for six months in the financial year 2010. Note that the data of the comprehensive Income Statement for the comparable annual reference period (01/01-31/12/2009) have been restated in order to include only continuing operations. Discontinued operations include the results of Avrupa Safak Hospital (member of Genesis Group) for the whole financial year 2010, after the agreement regarding its being transferred to existing shareholders and the results of Stem Health Unirea (Member of Stem Group), sold in August 2010 (Note 11 of the Annual Financial Statements Notes).
- The goodwill from the subsidiaries of Turkey, Cyprus and MITERA SA was impaired in the current financial year and stands now at the amount of €186,5 m. (Note 12.2 of the Annual Financial Statements Notes.)
- HYGEIA S.A Group consolidated financial statements are included with the purchase method for the 4Q2009 in the consolidated financial statements of 'Marfin Investment Group Holdings S.A.' based in Greece, with 48,29% direct and indirect participation rate in D.T.C.A HYGEIA S.A.
- The Ordinary General Shareholders Meeting, held on June 7th 2010, decided inter alia to: a) decrease its share capital by €24,498,027.45 in order to return to shareholders € 0.15 per share with payment in cash with a respective decrease of the nominal value of each share by the amount of € 0.15, namely from € 0.56 to € 0.41, and b) increase of its share capital up to the amount of thirteen million three hundred ninety two million two hundred fifty four thousand and seventy six cents (€13.392.254,76) by issuing up to thirty two million six hundred sixty four thousand three hundred and thirty six (32,664,036) new registered shares of € 0.41 nominal value each, by virtue of shareholders option to reinvest capital return with payment in cash at share premium subscription price. The Company's share capital increased by €5,142,001.88 by issuing 12,541,468 new shares amounting to €72,103,276.91, divided in 175,861,651 common registered shares of €0.41 nominal value each. The share premium difference of € 6,270,734 was recorded in the account 'Difference from shares issue at share premium'. On 02.09.2010, decision no.K2-8361/02.09.2010 by the Minister of Economy, Competitiveness and Shipping was entered in the SAs Registry, whereby certifying the share capital increase and approving the modification of article 5, of the Company Articles of Association, by virtue of the option to reinvest part of the capital increase return. The Company's share capital amounts to seventy two million one hundred and three thousand two hundred seventy six and ninety one (€ 72.103.276,91) fully paid, divided in one hundred seventy five million eight hundred sixty one thousand six hundred fifty one common registered shares of € 0.41 nominal value each.
- The most important sub judice, the judicial decisions that have or may have important effect in the economic situation or in the operation of the Company and the Group amount circa to €65.7 m and €212 m respectively and they have to do with patients' or their heirs' requirements; part of the abovementioned amount is covered by Mal Practice insurance/(Note 12.33).
- The Company has formed a cumulative provision of about €1.4 m for litigation. For the Group, the respective provision amount stands at circa €9.6m. Substantial surcharges from other litigious or under arbitration disputes of the company and the Group and decisions of judicial instruments exceeding the provision already made are not expected to arise.
- The Company formed a cumulative provision of €450 thous. for unaudited financial years. For the Group, the respective provision amount stands at circa €1.9m. A relevant analysis on the unaudited financial years of every company is presented in Note 12.33 of the Annual Financial Statements Notes.
- The Group and the Company have not formed other provisions, in the meaning of paragraphs 10, 11 and 14 of IAS 37 'Provisions, Contingent Liabilities and Contingent Assets'.
- On 31.12.2010 the Group personnel totaled 4,647 employees (31.12.2009: 4,293) and the Company's personnel totaled 1,227 employees (31.12.2009: 1,154), respectively.
- The revenues/expenses amounts since the beginning of financial year 2010 resulting from transactions with related parties, according to IAS 24, are analyzed in the following table:

Amounts in thous €	Group	Company
Revenues	1,095,103	3,164,729
Expenses	14,186,000	33,926,682
Receivables	26,581,000	23,488,626
Liabilities	171,289,000	134,641,682
Transactions and payments of senior executives and administration members	7,610,754	2,651,616

- There are pledges on the Group's assets amounting to €14.1m. There are no pledges on the Company's assets.
- For the financial year 2010, the Company, due to losses, does not proceed to dividend distribution.
- The other total revenues for the period 01.01-31.12.2010 amount to (€ 396,969) and concern Fx translation differences from converting subsidiaries financial statements into the parent company operation currency (euro) and from changes in the equity from available for sale portfolio assessment. Respectively, other total revenues amount to €2,942,974 for the period 01.01-31.12.2009.
- At the end of the current period, there are no parent company shares held either by itself or by subsidiaries and affiliated entities.
- The most important events carried out posterior to December 31st 2010 are presented in Note 14 of the Annual Financial Statements.
- The Group and Parent financial statements dated 31.12.2010 were approved by the Company's BoD on 28.03.2011.
- The annual financial statements basic accounting policies of financial year 2009 have been observed.

Maroussi, March 28, 2011

BoD CHAIRMAN	CHIEF EXECUTIVE OFFICER	GROUP CFO	GROUP FINANCIAL CONTROLLER	DEPUTY CFO
KONSTANTINOS STAVROU	ARETI SOUVATZOGLOU	PANTELIS DIMOPOULOS	NIKOLAOS BILALIS	SPYRIDON KOSMAS
ID No. AH529814	ID No. AI091976	ID No. AB606210	ID No. AA005000	ID No. AZ 555377
			LICENSE NUMBER 58800-CLASS A'	LICENSE NUMBER 16310-CLASS A'